Edesa Biotech, Inc. (EDSA): Price and Financial Metrics
GET POWR RATINGS... FREE!
EDSA Stock Price Chart Interactive Chart >
EDSA Price/Volume Stats
| Current price | $1.36 | 52-week high | $4.42 |
| Prev. close | $1.37 | 52-week low | $0.76 |
| Day low | $1.32 | Volume | 64,735 |
| Day high | $1.40 | Avg. volume | 391,600 |
| 50-day MA | $1.52 | Dividend yield | N/A |
| 200-day MA | $1.58 | Market Cap | 26.32M |
Edesa Biotech, Inc. (EDSA) Company Bio
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Latest EDSA News From Around the Web
Below are the latest news stories about EDESA BIOTECH INC that investors may wish to consider to help them evaluate EDSA as an investment opportunity.
Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo StudyCompany''s biologic drug candidate targets a key pathway involved in the progression and maintenance of depigmentation. TORONTO, ON / ACCESSWIRE / February 1, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has received approval from Health Canada for a Phase 2 clinical study of the company''s EB06 monoclonal antibody candidate as a treatment for vitiligo. Vitiligo is a life-altering autoimmune disease that causes skin to lose its color in patches. While it can affect any area, vitiligo commonly occurs on the face, neck and hands, and is a lifelong condition. According to the World Health Organization, vitiligo affects approximately 1% of the world''s population. Par Nijhawa... |
EDSA: 1.0% EB01 Cream Achieves Primary Endpoint in Phase 2b Trial…By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update 1.0% EB01 Cream Achieves Primary Endpoint in Phase 2b Trial On January 17, 2023, Edesa Biotech, Inc. (NASDAQ:EDSA) announced topline results for the Phase 2b clinical trial of EB01 as a treatment for chronic moderate-to-severe Allergic Contact Dermatitis (ACD). The double blind, placebo controlled trial evaluated |
Edesa Biotech''s Dermatitis Study Data Fails To Cheer InvestorsEdesa Biotech Inc (NASDAQ: EDSA ) announced preliminary topline results from a Phase 2b study evaluating multiple concentrations of the company''s drug candidate, EB01, as monotherapy for moderate-to-severe chronic Allergic Contact Dermatitis. EB01 is a non-steroidal anti-inflamamatory compound that inhibits secretory phospholipase 2. Edesa reported that 1.0% EB01 cream demonstrated statistically significant improvement over … Full story available on Benzinga.com |
Edesa Biotech Plunges on ACD Treatment NewsHealthcare stocks, particularly pharmaceutical stocks, have often given their investors headaches. Edesa Biotech (NASDAQ:EDSA) is joining the ranks… |
Neovasc, Aligos top healthcare gainers; Edesa, Angion lead losers'' packNeovasc NVCN +30%. Aligos Therapeutics (ALGS) +25%. Edesa Biotech EDSA -34%. Angion Biomedica ANGN -29%. |
EDSA Price Returns
| 1-mo | -48.29% |
| 3-mo | 51.09% |
| 6-mo | -33.98% |
| 1-year | -66.99% |
| 3-year | -57.89% |
| 5-year | -95.85% |
| YTD | -37.04% |
| 2022 | -61.63% |
| 2021 | 32.47% |
| 2020 | 3.66% |
| 2019 | -24.91% |
| 2018 | -83.95% |
Loading social stream, please wait...